T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
- Sponsor
- Imperial College London
- Study ID
- NCT01060098
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- anti-TNF therapy (etanercept or adalimumab) — DRUGBiological DMARD
Study Details
We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National Health Service) trusts will be recruited. We will correlate disease activity assessed by clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and target tissues, such as synovium and skin.
Key Dates
- Start date
- Apr 30, 2010
- Status verified
- Jan 2020
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 48 participants (actual)
Arms
- Arm: Rheumatoid arthritisParticipants with Rheumatoid arthritis
- Arm: Ankylosing spondylitisParticipants with Ankylosing spondylitis
- Arm: Psoriatic arthritisParticipants with Psoriatic arthritis
Primary Outcome Measure
Measurement of Effector T Helper Type 17 Cells in Peripheral Blood [ Time Frame: Week 0, Week 12 ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska